CL2018003050A1 - Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas. - Google Patents
Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas.Info
- Publication number
- CL2018003050A1 CL2018003050A1 CL2018003050A CL2018003050A CL2018003050A1 CL 2018003050 A1 CL2018003050 A1 CL 2018003050A1 CL 2018003050 A CL2018003050 A CL 2018003050A CL 2018003050 A CL2018003050 A CL 2018003050A CL 2018003050 A1 CL2018003050 A1 CL 2018003050A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- angle
- wnt
- disorders
- signaling
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SE DIVULGAN COMPUESTOS DE ISOQUINOLINA PARA EL TRATAMIENTO DE DIVERSAS ENFERMEDADES Y PATOLOGÍAS. MÁS CONCRETAMENTE, LA PRESENTE DIVULGACIÓN SE REFIERE AL USO DE UN COMPUESTO DE ISOQUINOLINA, O ANÁLOGOS DE LA MISMA, EN EL TRATAMIENTO DE TRASTORNOS CARACTERIZADOS POR LA ACTIVACIÓN DE LA SEÑALIZACIÓN DE LA VÍA WNT (POR EJEMPLO, CÁNCER, PROLIFERACIÓN CELULAR ANORMAL, ANGIOGÉNESIS, ENFERMEDAD DE ALZHEIMER, ENFERMEDAD PULMONAR, INFLAMACIÓN, ENFERMEDADES AUTOINMUNITARIAS Y ARTROSIS), LA MODULACIÓN DE LOS EVENTOS CELULARES MEDIADOS POR LA SEÑALIZACIÓN DE LA VÍA WNT, ASÍ COMO LAS AFECCIONES/LOS TRASTORNOS/LAS ENFERMEDADES NEUROLÓGICOS RELACIONADOS CON LA SOBREEXPRESIÓN DE DYRK1A.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662328210P | 2016-04-27 | 2016-04-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018003050A1 true CL2018003050A1 (es) | 2019-01-25 |
Family
ID=60157342
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018003050A CL2018003050A1 (es) | 2016-04-27 | 2018-10-26 | Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas. |
CL2019002067A CL2019002067A1 (es) | 2016-04-27 | 2019-07-24 | Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas. (divisional solicitud 201803050). |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019002067A CL2019002067A1 (es) | 2016-04-27 | 2019-07-24 | Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas. (divisional solicitud 201803050). |
Country Status (19)
Country | Link |
---|---|
US (5) | US10508099B2 (es) |
EP (2) | EP3943086A1 (es) |
JP (1) | JP7023243B2 (es) |
KR (1) | KR102399206B1 (es) |
CN (1) | CN109311819B (es) |
AR (1) | AR108326A1 (es) |
AU (1) | AU2017258187B2 (es) |
BR (1) | BR112018072190A2 (es) |
CA (1) | CA3022044A1 (es) |
CL (2) | CL2018003050A1 (es) |
CO (1) | CO2018012655A2 (es) |
IL (1) | IL262495B (es) |
MA (1) | MA43605B1 (es) |
MX (1) | MX2018013173A (es) |
PE (1) | PE20190260A1 (es) |
PH (1) | PH12018502259A1 (es) |
RU (1) | RU2018141379A (es) |
SG (2) | SG11201809310PA (es) |
WO (1) | WO2017189823A2 (es) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10975068B2 (en) | 2016-04-27 | 2021-04-13 | Janssen Pharmaceutica Nv | 6-aminopyridin-3-yl thiazoles as modulators of RORγT |
US10975057B2 (en) | 2018-06-18 | 2021-04-13 | Janssen Pharmaceutica Nv | 6-aminopyridin-3-yl pyrazoles as modulators of RORgT |
US11034658B2 (en) | 2018-06-18 | 2021-06-15 | Janssen Pharmaceutica Nv | Pyridinyl pyrazoles as modulators of RORγT |
US11345666B2 (en) | 2018-06-18 | 2022-05-31 | Janssen Pharmaceutica Nv | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9604930B2 (en) | 2012-12-21 | 2017-03-28 | Epizyme, Inc. | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof |
AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
KR20190135029A (ko) | 2017-03-30 | 2019-12-05 | 에프. 호프만-라 로슈 아게 | Hpk1의 억제제인 이소퀴놀린 |
JP2020537667A (ja) * | 2017-10-17 | 2020-12-24 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体m4のアンタゴニスト |
US10604514B2 (en) * | 2017-10-19 | 2020-03-31 | Samumed, Llc | 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof |
WO2019084497A1 (en) | 2017-10-27 | 2019-05-02 | Samumed, Llc | 6- (HETEROARYL AND ARYL WITH 6 CHAINS) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE |
US10413537B2 (en) | 2017-10-27 | 2019-09-17 | Samumed, Llc | 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof |
US10703748B2 (en) | 2017-10-31 | 2020-07-07 | Samumed, Llc | Diazanaphthalen-3-yl carboxamides and preparation and use thereof |
WO2019243999A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Phenyl substituted pyrazoles as modulators of roryt |
TW202024053A (zh) | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
WO2021004547A1 (en) * | 2019-07-11 | 2021-01-14 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of hpk1 |
WO2021042911A1 (zh) * | 2019-09-05 | 2021-03-11 | 鲁南制药集团股份有限公司 | Magl抑制剂及其制备方法、用途 |
WO2022093881A1 (en) * | 2020-10-29 | 2022-05-05 | Merck Sharp & Dohme Corp. | N-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
EP4294798A1 (en) * | 2021-02-19 | 2023-12-27 | Kalvista Pharmaceuticals Limited | Factor xiia inhibitors |
WO2023055679A1 (en) * | 2021-10-01 | 2023-04-06 | Merck Sharp & Dohme Llc | C-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
WO2023107714A2 (en) * | 2021-12-10 | 2023-06-15 | Prothena Biosciences Limited | Methods for treating neurological disorders |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4164559A (en) | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
ES2131463B1 (es) * | 1997-04-08 | 2000-03-01 | Lilly Sa | Derivados de ciclopropilglicina con propiedades farmaceuticas. |
DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
US6440102B1 (en) | 1998-07-23 | 2002-08-27 | Durect Corporation | Fluid transfer and diagnostic system for treating the inner ear |
DE19853299C2 (de) | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs |
US6120484A (en) | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
US6648873B2 (en) | 2001-09-21 | 2003-11-18 | Durect Corp. | Aural catheter system including anchor balloon and balloon inflation device |
GB0310867D0 (en) | 2003-05-12 | 2003-06-18 | Novartis Ag | Organic compounds |
US7008953B2 (en) | 2003-07-30 | 2006-03-07 | Agouron Pharmaceuticals, Inc. | 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
CA2594963A1 (en) | 2005-01-24 | 2006-07-27 | Neurosystec Corporation | Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues |
WO2007125405A2 (en) * | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
NZ583351A (en) * | 2007-08-15 | 2012-05-25 | Cytokinetics Inc | Modulate smooth muscle myosin and/or non-muscle myosin |
DK2987487T3 (da) * | 2009-08-10 | 2020-12-07 | Samumed Llc | Indazolinhibitorer af wnt-signalvejen og terapeutiske anvendelser deraf |
JP2013501792A (ja) | 2009-08-10 | 2013-01-17 | サミュメッド リミテッド ライアビリティ カンパニー | Wnt/b−カテニンシグナル伝達経路阻害剤としてのインダゾールおよびその治療的使用 |
WO2011121555A1 (en) * | 2010-03-31 | 2011-10-06 | Actelion Pharmaceuticals Ltd | Antibacterial isoquinolin-3-ylurea derivatives |
WO2012080284A2 (en) | 2010-12-17 | 2012-06-21 | F. Hoffmann-La Roche Ag | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof |
BR112014006127A2 (pt) | 2011-09-14 | 2017-04-04 | Samumed Llc | indazol-3-carboxamidas e sua utilização como inibidores da via de sinalização wnt/b-catenina |
WO2013169793A2 (en) * | 2012-05-09 | 2013-11-14 | Ipierian, Inc. | Methods and compositions for tdp-43 proteinopathies |
US9557993B2 (en) | 2012-10-23 | 2017-01-31 | Analog Devices Global | Processor architecture and method for simplifying programming single instruction, multiple data within a register |
WO2015143380A1 (en) | 2014-03-20 | 2015-09-24 | Samumed, Llc | 5-substituted indazole-3-carboxamides and preparation and use thereof |
GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
EP3813826A4 (en) | 2018-06-26 | 2022-07-06 | BioSplice Therapeutics, Inc. | METHOD OF TREATMENT OF CANCER USING A CLK INHIBITOR |
-
2017
- 2017-04-26 AR ARP170101056A patent/AR108326A1/es unknown
- 2017-04-27 KR KR1020187034080A patent/KR102399206B1/ko active IP Right Grant
- 2017-04-27 US US15/498,990 patent/US10508099B2/en active Active
- 2017-04-27 BR BR112018072190-5A patent/BR112018072190A2/pt not_active IP Right Cessation
- 2017-04-27 CA CA3022044A patent/CA3022044A1/en active Pending
- 2017-04-27 JP JP2018556921A patent/JP7023243B2/ja active Active
- 2017-04-27 CN CN201780037470.7A patent/CN109311819B/zh active Active
- 2017-04-27 AU AU2017258187A patent/AU2017258187B2/en not_active Ceased
- 2017-04-27 MA MA43605A patent/MA43605B1/fr unknown
- 2017-04-27 PE PE2018002175A patent/PE20190260A1/es unknown
- 2017-04-27 MX MX2018013173A patent/MX2018013173A/es unknown
- 2017-04-27 SG SG11201809310PA patent/SG11201809310PA/en unknown
- 2017-04-27 EP EP21181038.7A patent/EP3943086A1/en not_active Withdrawn
- 2017-04-27 RU RU2018141379A patent/RU2018141379A/ru unknown
- 2017-04-27 SG SG10201914127PA patent/SG10201914127PA/en unknown
- 2017-04-27 EP EP17790411.7A patent/EP3448838B1/en active Active
- 2017-04-27 WO PCT/US2017/029797 patent/WO2017189823A2/en active Application Filing
-
2018
- 2018-03-19 US US15/925,157 patent/US10287267B2/en active Active
- 2018-04-03 US US15/943,864 patent/US10556885B2/en active Active
- 2018-10-21 IL IL262495A patent/IL262495B/en unknown
- 2018-10-23 PH PH12018502259A patent/PH12018502259A1/en unknown
- 2018-10-26 CL CL2018003050A patent/CL2018003050A1/es unknown
- 2018-11-23 CO CONC2018/0012655A patent/CO2018012655A2/es unknown
-
2019
- 2019-07-24 CL CL2019002067A patent/CL2019002067A1/es unknown
- 2019-12-26 US US16/727,053 patent/US11174244B2/en active Active
-
2021
- 2021-10-06 US US17/495,281 patent/US11673881B2/en active Active
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10975068B2 (en) | 2016-04-27 | 2021-04-13 | Janssen Pharmaceutica Nv | 6-aminopyridin-3-yl thiazoles as modulators of RORγT |
US10975057B2 (en) | 2018-06-18 | 2021-04-13 | Janssen Pharmaceutica Nv | 6-aminopyridin-3-yl pyrazoles as modulators of RORgT |
US11034658B2 (en) | 2018-06-18 | 2021-06-15 | Janssen Pharmaceutica Nv | Pyridinyl pyrazoles as modulators of RORγT |
US11345666B2 (en) | 2018-06-18 | 2022-05-31 | Janssen Pharmaceutica Nv | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018003050A1 (es) | Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas. | |
CL2018003065A1 (es) | Isoquinolin-3-il-carboxamidas y preparación y uso de las mismas. | |
ECSP19003773A (es) | Compuestos heterocíclicos como inmunomoduladores | |
CL2018002794A1 (es) | Compuestos bicíclicos | |
UY37957A (es) | Moduladores de la vía de estrés integrada | |
CL2015002529A1 (es) | Compuestos de tetrahidropirrolotiazina | |
UY37956A (es) | Moduladores de la vía de estrés integrada | |
AR128259A2 (es) | Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofílica | |
CL2016001595A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6. | |
UY37645A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
BR112018003634A8 (pt) | Processo para preparar um inibidor parp, formas cristalinas e usos destes | |
CR20160222U (es) | Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas | |
UY37646A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
UY35023A (es) | Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso | |
ECSP14020640A (es) | Inhibidores de la beta-secretasa | |
CL2019003213A1 (es) | Compuestos plaguicidas bicíclicos. | |
UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
UY36629A (es) | Indazolonas como moduladores de la señalización de tnf | |
CO7111276A2 (es) | Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met | |
UY35357A (es) | Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa n eutrofílica | |
CL2016002089A1 (es) | Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
DK3515918T3 (da) | Fremgangsmåde til fremstilling af 2-exo-(2-methylbenzyloxy)-1-methyl-4-isopropyl-7-oxabicyclo[2.2.1]heptan | |
CL2020002177A1 (es) | Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparación y uso de las mismas | |
UY35746A (es) | Derivados de fenilalanina sustituidos | |
CL2017000117A1 (es) | Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrófila. |